Leukemia Immunotherapy After Allogeneic Transplant
Leukemia Immunotherapy After Allogeneic Transplant
批准号:
7385986
负责人:
CRAIG A MULLEN
金额:
$27.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-04-01 至 2011-02-28
关键词:
Active ImmunizationAcuteAcute leukemiaAffinityAllogenicAntigen TargetingAntigensCD8B1 geneCancer VaccinesCellsChildChildhood LeukemiaClassClinicalDataDevelopmentDown-RegulationEnvironmentExhibitsFailureGene ExpressionGenesGoalsHematopoietic Stem Cell TransplantationHematopoietic stem cellsHumanHuman Placental LactogenHybridomasImmuneImmune responseImmunotherapyInfusion proceduresInvestigationLaboratoriesLymphocyteMalignant NeoplasmsMinor Histocompatibility AntigensModelingMusNatural Killer CellsNeoplasm TransplantationOrganPatientsPreparationProcessRelapseRelative (related person)Reporter GenesResearchResearch PersonnelResidual stateStem cell transplantT-LymphocyteTestingTherapeuticTransplant RecipientsTransplantationVaccinationVaccinesWorkbaseclinically significantdesignexperienceexpression cloninggraft vs host diseasehigh throughput screeningleukemiaprogramsresponsetherapy designvaccine efficacy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of this research is to use murine models of allogeneic hematopoietic stem cell (HSC) transplantation to identify immunological mechanisms that can be used to design therapies that will reduce the likelihood of leukemia relapse after allogeneic HCS transplant in children with leukemia. In allogeneic HSC transplant the graft versus leukemia (GVL) effect is closely associated with GVHD and clinical attempts to separate the two have not been successful. In the absence of specific immune manipulation the dominant allogeneic immune response that develops after transplant is directed at immunodominant, widely distributed host antigens, and the post-transplant environment does not favor development of immune responses with relative selectively for antigens on minimal residual leukemia. The applicant's laboratory has recently demonstrated that allogeneic HSC transplant recipients treated after transplant with cellular tumor vaccines exhibit prolonged survival but do not experience exacerbations of GVHD. The mechanism of this vaccine effect is under investigation. Hypothesis: Post-transplant tumor vaccines can enhance systemic immune responses that can control minimal residual leukemia without exacerbation of clinically significant graft versus host disease.
Specific Aim 1: To test the hypothesis that after allogeneic hematopoietic stem cell transplantation moderate affinity T cells specific for subdominant minor histocompatibility antigens can be activated by vaccines to exert antileukemia activity without GVHD.
Specific Aim 2: To test the hypothesis that allogeneic delayed lymphocyte infusion for acute lymphoblastic malignancies can be made more effective by simultaneous vaccination against leukemia associated antigens.
Specific Aim 3: To identify the leukemia associated antigenic targets of T cells induced by post-transplant tumor vaccines and to determine if these empirically identified genes correlate with classes of genes predicted to be antigenic based on gene expression analysis.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Evidence of B cell immune responses to acute lymphoblastic leukemia in murine allogeneic hematopoietic stem cell transplantation recipients treated with donor lymphocyte infusion and/or vaccination.
在接受供体淋巴细胞输注和/或疫苗接种治疗的小鼠同种异体造血干细胞移植受者中,B 细胞对急性淋巴细胞白血病产生免疫反应的证据。
DOI:
10.1016/j.bbmt.2010.08.021
发表时间:
2011
期刊:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
影响因子:
--
作者:
[Mullen,CraigA, Campbell,Andrew, Tkachenko,Olena, Jansson,Johan, Hsu,Yu-Chiao]
通讯作者:
Hsu,Yu-Chiao
High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
具有 bcr-abl 和 INK4A/ARF 突变的高危急性淋巴细胞白血病细胞保留对同种异体反应性 T 细胞的敏感性。
DOI:
10.1016/j.bbmt.2008.02.015
发表时间:
2008
期刊:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
影响因子:
--
作者:
[Young,FaithM, Campbell,Andrew, Emo,KrisLambert, Jansson,Johan, Wang,Pin-Yi, Jordan,CraigT, Mullen,CraigA]
通讯作者:
Mullen,CraigA
Acute lymphoid leukemia cells with greater stem cell antigen-1 (Ly6a/Sca-1) expression exhibit higher levels of metalloproteinase activity and are more aggressive in vivo.
干细胞抗原 1 (Ly6a/Sca-1) 表达较高的急性淋巴细胞白血病细胞表现出较高水平的金属蛋白酶活性,并且在体内更具侵袭性。
DOI:
10.1371/journal.pone.0088966
发表时间:
2014
期刊:
PloS one
影响因子:
3.7
作者:
[Hsu,Yu-Chiao, Mildenstein,Kurt, Hunter,Kordell, Tkachenko,Olena, Mullen,CraigA]
通讯作者:
Mullen,CraigA
Predictive Mathematical Models for Rational Design of Chemoimmunotherapy of Leuke
-
批准号:7942791
-
项目类别:
-
资助金额:$34.86万
-
财政年份:2009
-
负责人:CRAIG A MULLEN
-
依托单位:
Predictive Mathematical Models for Rational Design of Chemoimmunotherapy of Leuke
-
批准号:7818617
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2009
-
负责人:CRAIG A MULLEN
-
依托单位:
Leukemia Immunotherapy After Allogeneic Transplant
-
批准号:6863669
-
项目类别:
-
资助金额:$39.14万
-
财政年份:2004
-
负责人:CRAIG A MULLEN
-
依托单位:
Leukemia Immunotherapy After Allogeneic Transplant
-
批准号:7026474
-
项目类别:
-
资助金额:$29.29万
-
财政年份:2004
-
负责人:CRAIG A MULLEN
-
依托单位:
Leukemia Immunotherapy After Allogeneic Transplant
-
批准号:7195075
-
项目类别:
-
资助金额:$27.55万
-
财政年份:2004
-
负责人:CRAIG A MULLEN
-
依托单位:
Leukemia Immunotherapy After Allogeneic Transplant
-
批准号:6755742
-
项目类别:
-
资助金额:$27.88万
-
财政年份:2004
-
负责人:CRAIG A MULLEN
-
依托单位:
海外基金